Summary

Blue Biotechnology Market Research Report Information by Product (Enzymes, Pharma Products, Bulk Chemicals, and Others), by Application (Bioengineering, Genomics, Vaccine Development, Drug Discovery, Fisheries, Aquaculture, Biofuels, Water Treatment Services, and Others), and by End User (Hospitals, Pharmaceutical Companies, Biotechnology Companies, and Others) and by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

Market Overview
During the forecast period (2024-2032), the Blue Biotechnology Market industry is anticipated to experience a compound annual growth rate (CAGR) of 7.15%, increasing from USD 5.65 billion in 2024 to USD 10.54 billion by 2032. Strategic initiatives associated with pharmaceuticals and nutraceuticals sourced from marine organisms, as well as the growing awareness of blue biotechnology-based nutraceuticals and pharmaceuticals, are the factors that are fueling the growth of the global market.
The blue biotechnology market is experiencing significant development as a result of the growing recognition of nutraceuticals and pharmaceuticals that are based on blue biotechnology. The demand for products derived from marine organisms is increasing as consumers become more aware of the health benefits provided by marine-derived compounds. The perceived health-promoting properties of nutraceuticals that contain marine ingredients, such as omega-3 fatty acids, antioxidants, and minerals, are causing them to acquire popularity.
In addition, the Blue Biotechnology Market is being significantly influenced by the rise in strategic initiatives that are focused on pharmaceutical and nutraceutical products that are derived from marine organisms. The pharmaceutical and nutraceutical industries have shifted their attention to the oceans' vast and largely untapped resources as they seek new methods to meet evolving healthcare and dietary needs.

Market segment insights
The Blue Biotechnology Market is segmented into enzymes, pharma products, bulk chemicals, biopolymers, and others based on product.
The Blue Biotechnology Market has been categorized into the following by type: bioengineering, genomics, vaccine development, drug discovery, fisheries, aquaculture, biofuels, water purification services, and others.
The blue biotechnology market is segmented into hospitals, pharmaceutical companies, biotechnology companies, and others based on the end user.

Regional Perspectives

The market is segmented into four regions: North America, Europe, Asia-Pacific, and the Rest of the World. In 2023, North America held the largest market share of over 36.04%, which was attributed to the presence of established drug manufacturers, advanced healthcare infrastructure, and increased investment in research and development activities. Furthermore, the region's market growth is being stimulated by the active involvement of renowned market actors in meeting consumer demand.
The blue biotechnology market in Europe is expected to experience substantial growth during the forecast year, 2024–2032, because of the substantial number of start-ups that are associated with blue biotechnology. For example, the Oceano Azul Foundations and Calouste Gulbenkian, both of which are based in Portugal, received over 120 projects from more than 30 countries that were associated with blue biotechnology by September 2020.
The Asia-Pacific blue biotechnology market is the fastest-growing region during the forecast period due to the high demand for marine-derived products in a variety of industries, including agriculture, pharmaceuticals, and cosmetics. Additionally, the market is experiencing significant growth because of the development of biotechnological tools and techniques, including genomics, proteomics, and metabolomics, which have facilitated the investigation and exploitation of marine resources. These technologies enable researchers to more effectively identify, isolate, and produce valuable compounds from marine organisms.

Major Players
Marinomed Biotech AG (Austria), Marshall Marine Products (India), Marinova (Australia), Aker BioMarine (Norway), Pharma Mar (Spain), Cyanotech Corporation (US), ADM (US), Geomarine (India), CP Kelco U.S., Inc. (US), and TerSera Therapeutics LLC (US) are among the key companies in the Blue Biotechnology Market.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING AWARENESS OF BLUE BIOTECHNOLOGY-BASED NUTRACEUTICALS AND PHARMACEUTICALS
4.2.2 RISING STRATEGIC INITIATIVES ASSOCIATED WITH PHARMACEUTICALS AND NUTRACEUTICALS SOURCED FROM MARINE ORGANISMS
4.3 RESTRAINTS
4.3.1 STRINGENT REGULATORY POLICIES
4.4 OPPORTUNITIES
4.4.1 INCREASING INVESTMENT IN THE DEVELOPMENT OF BIOTECHNOLOGY-BASED MEDICINE
5 MARKET FACTOR ANALYSIS
5.1 PORTER'S FIVE FORCES MODEL
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 BARGAINING POWER OF SUPPLIERS
5.1.3 THREAT OF SUBSTITUTES
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON THE INDIA CELL CULTURE MEDIA MARKET
5.2.1 IMPACT ON SUPPLY CHAIN
6 GLOBAL BLUE BIOTECHNOLOGY MARKET, BY PRODUCT
6.1 OVERVIEW
6.2 ENZYMES
6.3 PHARMA PRODUCTS
6.4 BULK CHEMICALS
6.5 BIOPOLYMERS
6.6 OTHERS
7 GLOBAL BLUE BIOTECHNOLOGY MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 BIOENGINEERING
7.3 GENOMICS
7.4 VACCINE DEVELOPMENT
7.5 DRUG DISCOVERY
7.6 FISHERIES
7.7 AQUACULTURE
7.8 BIOFUELS
7.9 WATER TREATMENT SERVICES
7.10 OTHERS
8 GLOBAL BLUE BIOTECHNOLOGY MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS
8.3 PHARMACEUTICAL COMPANIES
8.4 BIOTECHNOLOGY COMPANIES
8.5 OTHERS
9 GLOBAL BLUE BIOTECHNOLOGY MARKET, BY REGION
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.3 EUROPE
9.3.1 GERMANY
9.3.2 FRANCE
9.3.3 UK
9.3.4 ITALY
9.3.5 SPAIN
9.3.6 NORWAY
9.3.7 NETHERLANDS
9.3.8 SWITZERLAND
9.3.9 FINLAND
9.3.10 BELGIUM
9.3.11 REST OF EUROPE
9.4 ASIA-PACIFIC
9.4.1 CHINA
9.4.2 INDIA
9.4.3 JAPAN
9.4.4 AUSTRALIA
9.4.5 SOUTH KOREA
9.4.6 REST OF ASIA-PACIFIC
9.5 REST OF THE WORLD
9.5.1 LATIN AMERICA
9.5.2 MIDDLE EAST
9.5.3 AFRICA
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPETITIVE BENCHMARKING
10.3 MAJOR GROWTH STRATEGY IN THE BLUE BIOTECHNOLOGY MARKET
10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE BLUE BIOTECHNOLOGY MARKET
10.5 KEY DEVELOPMENT ANALYSIS
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
10.6.1 PRODUCT LAUNCH / PRODUCT APPROVAL
10.6.2 AGREEMENT
10.6.3 PARTNERSHIP
10.6.4 ACQUISITION
10.7 MAJOR PLAYERS FINANCIAL
10.7.1 SALES (USD MILLION), 2023
10.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2023
11 COMPANY PROFILES
11.1 MARINOMED BIOTECH AG
11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL OVERVIEW
11.1.3 PRODUCTS OFFERED
11.1.4 KEY DEVELOPMENTS
11.1.5 KEY STRATEGIES
11.2 MARSHALL MARINE PRODUCTS/
11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL OVERVIEW
11.2.3 PRODUCTS OFFERED
11.2.4 KEY DEVELOPMENTS
11.2.5 KEY STRATEGIES
11.3 MARINOVA
11.3.1 COMPANY OVERVIEW
11.3.2 FINANCIAL OVERVIEW
11.3.3 PRODUCTS OFFERED
11.3.4 KEY DEVELOPMENTS
11.3.5 SWOT ANALYSIS
11.3.6 KEY STRATEGIES
11.4 AKER BIOMARINE
11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL OVERVIEW
11.4.3 PRODUCTS OFFERED
11.4.4 KEY DEVELOPMENTS
11.4.5 SWOT ANALYSIS
11.4.6 KEY STRATEGIES
11.5 PHARMAMAR
11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL OVERVIEW
11.5.3 PRODUCTS OFFERED
11.5.4 KEY DEVELOPMENTS
11.5.5 SWOT ANALYSIS
11.5.6 KEY STRATEGIES
11.6 CYANOTECH CORPORATION
11.6.1 COMPANY OVERVIEWS
11.6.2 FINANCIAL OVERVIEW
11.6.3 PRODUCTS OFFERED
11.6.4 KEY DEVELOPMENTS
11.6.5 KEY STRATEGIES
11.7 ADM
11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL ANALYSIS
11.7.3 PRODUCTS OFFERED
11.7.4 KEY DEVELOPMENTS
11.7.5 SWOT ANALYSIS
11.7.6 KEY STRATEGIES
11.8 GEOMARINE BIOTECHNOLOGIES
11.8.1 COMPANY OVERVIEW
11.8.2 FINANCIAL OVERVIEW
11.8.3 PRODUCTS OFFERED
11.8.4 KEY DEVELOPMENTS
11.8.5 KEY STRATEGIES
11.9 CP KELCO U.S., INC.
11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL OVERVIEW
11.9.3 PRODUCT OFFERED
11.9.4 KEY DEVELOPMENTS
11.9.5 KEY STRATEGIES
11.10 TERSERA THERAPEUTICS LLC
11.10.1 COMPANY OVERVIEW
11.10.2 FINANCIAL OVERVIEW
11.10.3 PRODUCTS OFFERED
11.10.4 KEY DEVELOPMENTS
11.10.5 SWOT ANALYSIS
11.10.6 KEY STRATEGIES
12 APPENDIX
12.1 REFERENCES
12.2 RELATED REPORTS